A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
Undevia, S. D., Kindler, H. L., Janisch, L., Olson, S. C., Schilsky, R. L., Vogelzang, N. J., Kimmel, K. A., Macek, T. A., Ratain, M. J.
Published in Annals of oncology (01.11.2004)
Published in Annals of oncology (01.11.2004)
Get full text
Journal Article
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Chugh, R, Griffith, K A, Davis, E J, Thomas, D G, Zavala, J D, Metko, G, Brockstein, B, Undevia, S D, Stadler, W M, Schuetze, S M
Published in Annals of oncology (01.08.2019)
Published in Annals of oncology (01.08.2019)
Get full text
Journal Article
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
Chugh, R., Griffith, K.A., Davis, E.J., Thomas, D.G., Zavala, J.D., Metko, G., Brockstein, B., Undevia, S.D., Stadler, W.M., Schuetze, S.M.
Published in Annals of oncology (01.07.2015)
Published in Annals of oncology (01.07.2015)
Get full text
Journal Article
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours
Undevia, Samir D, Innocenti, Federico, Ramirez, Jacqueline, House, Larry, Desai, Apurva A, Skoog, Linda A, Singh, Deepti A, Karrison, Theodore, Kindler, Hedy L, Ratain, Mark J
Published in European journal of cancer (1990) (01.08.2008)
Published in European journal of cancer (1990) (01.08.2008)
Get full text
Journal Article
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT)
O'Donnell, P. H., Artz, A. S., Undevia, S. D., Hart, J., van Besien, K.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
INNOCENTI, Federico, UNDEVIA, Samir D, VOKES, Everett E, RATAIN, Mark J, IYER, Lalitha, PEI XIAN CHEN, DAS, Soma, KOCHERGINSKY, Masha, KARRISON, Theodore, JANISCH, Linda, RAMIREZ, Jacqueline, RUDIN, Charles M
Published in Journal of clinical oncology (15.04.2004)
Published in Journal of clinical oncology (15.04.2004)
Get full text
Journal Article
Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial
Schwartz, G. K., Maki, R. G., Ratain, M. J., Undevia, S. D., Jones, R. L., Rudin, C. M., Siu, L. L., Brockstein, B., Khayat, D., Gil, T., De Jonge, M. J., Sawyer, M. B., Evans, T. R. J., Medioni, J., O'Dwyer, P. J., Hartman, C., Poulart, V., Walters, I. B.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Pharmacokinetic variability of anticancer agents
Ratain, Mark J, Undevia, Samir D, Gomez-Abuin, Gonzalo
Published in Nature reviews. Cancer (01.06.2005)
Published in Nature reviews. Cancer (01.06.2005)
Get full text
Journal Article
Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060
Maki, R. G., Keohan, M. L., Undevia, S. D., Livingston, M., Cooney, M. M., Elias, A., Saulle, M. F., Wright, J. J., D’Adamo, D. R., Schuetze, S. M.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations
Bruce, J. Y., Geary, D., de las Heras, B., Soto, A., Garcia Paramio, P., Yovine, A., Schilsky, R. L., Undevia, S. D., Ratain, M. J.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781
Undevia, S. D., Janisch, L., Schilsky, R. L., Loury, D., Balasubramanian, S., Mani, C., Sirisawad, M., Buggy, J. J., Miller, R. A., Ratain, M. J.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies
Gangadhar, T., Cohen, E. E., Janisch, L., House, L. K., Undevia, S. D., Fleming, G. F., Maitland, M. L., Ramirez, J., Ratain, M. J.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic αvβ3 and αvβ5 integrin antagonist, in patients with advanced solid malignancy
Undevia, S. D., Janisch, L., Stadler, W. M., Wittemer, S. M., Ratain, M. J.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Phase I study of rapamycin (R) in combination with CYP3A4 modifier, ketoconazole (K), in patients with advanced malignancies
Cohen, E. E., Moshier, K., Innocenti, F., Kocherginsky, M., House, L., Ramirez, J., Undevia, S. D., Fleming, G. F., Ratain, M. J.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway
Maitland, M. L., Moshier, K., Imperial, J., Kasza, K. E., Karrison, T., Elliott, W., Undevia, S. D., Stadler, W., Desai, A. A., Ratain, M. J.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Patients (pts) understanding of phase II trial designs and informed consent (IC)
Undevia, S. D., Hlubocky, F. J., Goh, B. C., Ratain, M. J., Daugherty, C. K.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Patients (pts) understanding of phase II trial designs and informed consent (IC)
Undevia, S. D., Hlubocky, F. J., Goh, B. C., Ratain, M. J., Daugherty, C. K.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes
Innocenti, F., Undevia, S. D., Rosner, G. L., Xiao, L., Liu, W., Chen, P., Das, S., Ramirez, J., Kroetz, D. L., Ratain, M. J.
Published in Journal of clinical oncology (01.06.2005)
Published in Journal of clinical oncology (01.06.2005)
Get full text
Journal Article
Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2
Innocenti, F., Undevia, S. D., Chen, P. X., Das, S., Ramirez, J., Dolan, M. E., Relling, M. V., Kroetz, D. L., Ratain, M. J.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2
Innocenti, F., Undevia, S. D., Chen, P. X., Das, S., Ramirez, J., Dolan, M. E., Relling, M. V., Kroetz, D. L., Ratain, M. J.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article